Pricing Log in Create free account

Beam Therapeutics Inc. (BEAM) vs NewAmsterdam Pharma Company N.V. (NAMS)

Beam Therapeutics Inc. and NewAmsterdam Pharma Company N.V. are both Biotechnology companies. Beam Therapeutics Inc. and NewAmsterdam Pharma Company N.V. are of similar size ($2.6B and $2.5B). Beam Therapeutics Inc. grew revenue faster over the last twelve months: 158.9% against −88.9%. Beam Therapeutics Inc. has the higher net margin (−55.5% vs −3,644.2%) and the lower return on invested capital (−1,599.3% vs 0.00%). Across the 16 metrics below, Beam Therapeutics Inc. leads on 12 and NewAmsterdam Pharma Company N.V. on 4.

Valuation

Metric BEAM NAMS Biotechnology median
P/E n/m n/m 8.50
P/S 15.69 343.55 9.71
P/B 2.29 3.87 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 8.95 254.35 9.21
Earnings yield (3.49%) (10.89%) (33.15%)
Free cash flow yield (15.22%) (5.87%) (25.50%)

Profitability

Metric BEAM NAMS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (242.27%) (3,432.20%) 0.00%
Net margin (55.45%) (3,644.21%) 0.00%
Free cash flow margin (238.90%) (2,018.28%) 0.00%
Return on equity (8.18%) (36.81%) (56.36%)
Return on assets (6.23%) (34.16%) (48.04%)
Return on invested capital (1,599.30%) 0.00% 0.00%

Growth

Metric BEAM NAMS Biotechnology median
Revenue growth (TTM) 158.88% (88.87%) 6.02%
EPS growth (last fiscal year) 82.31% 32.81% 30.26%
Revenue growth, 5-year CAGR 466.27% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BEAM NAMS Biotechnology median
Debt to equity 0.09 0.00 0.00
Current ratio 14.57 9.03 4.72
Net debt to EBITDA 3.30 2.83 0.96

Dividend

Metric BEAM NAMS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BEAM NAMS Biotechnology median
Market cap 2.55b 2.46b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack